Skip to main content
Log in

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Since the poor prognosis associated with HER2 amplified breast cancers might be explained by a mechanistic association between p185HER2 overexpression and therapeutic resistance, we assessed the chemo-endocrine sensitivity of estrogen receptor (ER) containing MCF-7 breast cancer cells transfected with full-length HER2 cDNA. Of the 36 isolated MCF/HER2 subclones, 7 were found to overexpress p185HER2 surface receptor at levels 3 to 45-fold greater than parental or control transfected cells (MCF/neo). The overexpressing transfectants possessed increased inositol-1,4,5-trisphosphate-3'-kinase activity comparable to enzyme activity in the endogenously HER2 amplified breast cancer cell lines SK-Br-3 and BT-474. The anti-p185HER2 monoclonal antibody and receptor-specific partial agonist, muMAb4D5 (4D5), known to inhibit growth of SK-Br-3 and BT-474 cells, produced no significant growth inhibitory effect on any of the transfectants including the 45-fold overexpressing MCF/HER2–18 cells which were studied in greater detail. MCF/HER2–18 cells contained at least partially functioning exogenous receptor since 4D5 (3µg/ml) specifically stimulated phosphorylation of p185HER2 and its co-precipitating ptyr56 substrate within 5 min, and this was followed at 1 h by a transient induction ofc-myc but notc-fos mRNA. ER content and thein vitro sensitivity of MCF/HER2–18 cells to 5-fluorouracil and adriamycin were identical to those of control transfectants and parental cells. However, these highly overexpressing transfectants had acquired low level (2 to 4-fold) resistance to cisplatin and were no longer sensitive to the antiestrogen tamoxifen (TAM). To compare the hormone-dependent tumorigenicity of the HER2 transfectants, MCF/HER2–18 and control cells (MCF, MCF/neo-3) were implanted into ovariectomized athymic nude mice. No tumors were produced in the absence of estradiol (E2) administration. In E2 supplemented mice, MCF/HER2–18 tumors grew most rapidly. When E2 treatment was stopped and daily TAM injections were initiated, MCF-7 and MCF/neo-3 tumor growth ceased immediately, while MCF/HER2–18 tumors continued to show an accelerated growth rate lasting weeks. This pattern of hormone-dependent, TAM-resistant growth exhibited by the MCF/HER2–18 tumors in nude mice supports the possibility that p185HER2 overexpression in human breast cancers may be linked to therapeutic resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Scott GK, Dodson JM, Mongomery PA, Johnson RM, Sarup JC, Wong WL, Ullrich A, Shepard HM, Benz CC: p185HER2 signal transduction in breast cancer cells. J Biol Chem 266: 14300–14305, 1991

    PubMed  Google Scholar 

  2. Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Ullrich A, Shepard HM: Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor functions and inhibits tumor cell growth. Growth Regulation 1: 72–82, 1991

    PubMed  Google Scholar 

  3. Perren TJ: C-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63: 328–332, 1991

    PubMed  Google Scholar 

  4. Tripathy D, Benz CC: Activated oncogenes and putative tumor suppressor genes involved in human breast cancers. In: Benz CC, Liu E (eds) Oncogenes and Tumor Suppressor Genes in Human Malignancies. Kluwer Academic Publishers, Norwell, 1993 (in press)

    Google Scholar 

  5. Bauknecht T, Runge M, Schwall M,et al.: Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol 29: 147–157, 1988

    Article  PubMed  Google Scholar 

  6. Berchuck A, Kamel A, Whitaker R,et al.: Overexpression of Her-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50: 4087–4091, 1990

    PubMed  Google Scholar 

  7. Berns PMJJ, Klijn JGM, Van Staveren IL, Portengen H, Noordegraaf E, Foekens JA: Frequency and relevance of oncogene amplification in human breast tumors (abstract). Proc Am Assoc Cancer Res 32: 291, 1991

    Google Scholar 

  8. Wright C, Nicholson S, Angus B, Sainsburg JRC, Farndon J, Cairns J, Harris AL, Horne CHW: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65: 118–121, 1992

    PubMed  Google Scholar 

  9. Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinson S, Ullrich A: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location withneu oncogene. Science 230: 1132–1139, 1985

    PubMed  Google Scholar 

  10. Graham FL, van der Eb AJ: A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52: 456–467, 1973

    PubMed  Google Scholar 

  11. Hudziak RM, Lewis GD, Winget M, Fendly B, Shepard HM, Ullrich A: p185HER2 monoclonal antibody has antiproliferative effectsin vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165–1172, 1989

    PubMed  Google Scholar 

  12. Benz CC, Scott GK, Santos GF, Smith HS: Expression of c-myc, c-Ha-ras1, and c-erbB-2 proto-oncogenes in normal and malignant human breast epithelial cells. J Natl Cancer Inst 81: 1704–1709, 1989

    PubMed  Google Scholar 

  13. Liu E, Santos G, Lee WMF, Osborne CK, Benz CC: Effects of c-myc overexpression on the growth characteristics of MCF-7 human breast cancer cells. Oncogene 4: 979–984, 1989

    PubMed  Google Scholar 

  14. Johnson RM, Wasilenko WJ, Mattingly RR,et al.: Fibroblasts transformed with v-src show enhanced formation of an inositol tetrakisphosphate. Science 246: 121–124, 1989

    PubMed  Google Scholar 

  15. Osborne CK, Coronado EB, Robinson JP: Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 23: 1189–1196, 1987

    PubMed  Google Scholar 

  16. Berridge MJ, Irvine RF: Inositol phosphates and cell signalling. Nature 341: 197–205, 1989

    PubMed  Google Scholar 

  17. Pierre JH, Arnstein P, DiMarco E, Artip J, Kraus MH, Lonardo F, DiFiore PP, Aaronson SA: Oncogenic potential oferbB-2 in human mammary epithelial cells. Oncogene 6: 1189–1194, 1991

    PubMed  Google Scholar 

  18. Kasid A, Lippman ME, Papageorge AG, Lowy DR, Gelmann EP: Transfection of v-rasH DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. Science 228: 725–728, 1985

    PubMed  Google Scholar 

  19. Santos GF, Scott GK, Lee WMF, Liu E, Benz C: Estrogen-induced post-transcriptional modulation of c-myc proto-oncogene expression in human breast cancer cells. J Biol Chem 263: 9565–9568, 1988

    PubMed  Google Scholar 

  20. Christen RD, Hom DK, Porter DC, Andrews PA, MacLeod CL, Hafstrom L, Howell SB: Epidermal growth factor regulates thein vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 86: 1632–1640, 1990

    PubMed  Google Scholar 

  21. Isonishi S, Andrews PA, Howell SB: Increased sensitivity to cis-diamminedichloroplatinum (II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol-13-acetate. J Biol Chem 265: 3623–3627, 1990

    PubMed  Google Scholar 

  22. Isonishi S, Hom DK, Thiebaut FB,et al.: Expression of the c-Haras oncogene in mouse NIH3T3 cells induces resistance to cisplatin. Cancer Res 51: 5903–5909, 1991

    PubMed  Google Scholar 

  23. Osborne CK, Coronado E, Allred D, Wiebe V, DeGregorio M: Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxy-tamoxifen. J Natl Cancer Inst 83: 1477–1482, 1991

    PubMed  Google Scholar 

  24. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 48: 5183–5187, 1988

    PubMed  Google Scholar 

  25. Wiebe VJ, Osborne CK, McGuire WL, DeGregorio MW: Identification of estrogenic tamoxifen metabolites in tamoxifen-resistant human breast tumors. J Clin Oncol 10: 990–994, 1992

    PubMed  Google Scholar 

  26. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity ofcis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51: 4575–4580, 1991

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Benz, C.C., Scott, G.K., Sarup, J.C. et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu . Breast Cancer Res Tr 24, 85–95 (1992). https://doi.org/10.1007/BF01961241

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01961241

Key words

Navigation